Apr 24, 2023 · 1h 3m · capital-allocators
Rod Wong – Empty Rooms: Innovation in Biotech at RTW (Capital Allocators, EP. 310)
0:00 / 0:00
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of Capital Allocators, host Ted Seides interviews Rod Wong, founder of RTW Investments, exploring how specialized full-lifecycle investing, probabilistic trial underwriting, and disciplined organizational design drive outsized returns in biotechnology.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Ted holds 20.7% of the talking time here. How this is scored →
Ted as informed peer 5.0 Guest teaching 3.7 Guest disagreement 1.5 Ted pushing back 2.4
speaking balance: gold is Ted, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 29:05 Rod recounting the Map Pharma short squeeze acquisition
Rod highlights how market fundamentals can be upended by corporate maneuvering, forcefully warning against underestimating savvy business executives.
Hardest push from Ted ▶ 35:04 Ted challenging Rod on concentration versus dynamic volatilityTed openly pushes back against Rod's portfolio strategy, stating he scratches his head trying to reconcile high concentration with dynamic probabilities in a volatile sector.
Biggest teaching moment ▶ 41:10 Rod breaking down statistical traps in Phase 3 constipation trialsRod educates the audience on why pure statistical P-values fail in extended trials due to real-world patient behavior and OTC medication access.
Ted holds their own ▶ 38:53 Ted challenging hit rates against diversificationTed leverages quantitative portfolio logic to press Rod on why RTW stays concentrated when holding a win rate well above typical market benchmarks.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Ted as informed peer | Guest teaching | Guest disagreement | Ted pushing back | Why |
|---|---|---|---|---|---|---|
| Spread the Word: AI Voice Cloning Experiment | 4 | 2 | 1 | 2 | Ted opens with a playful AI voice cloning intro before transitioning into Rod's background. Ted probes how Rod went 'off the rails' from science into finance, prompting a lighthearted overview of his career trajectory. | |
| Navigating Biotech Investing within Multi-Strategy Platforms | 5 | 4 | 2 | 3 | Ted asks how long-duration, volatile biotech investing fits inside a risk-controlled multi-strategy shop like Davidson Kempner. Rod explains why biotech rarely fits comfortably in broader firms due to idiosyncratic volatility and specialized language barriers. | |
| Biotech Commercial Dynamics: Drug Pricing vs. Volume | 6 | 4 | 2 | 3 | Ted frames the economic dilemma of drug innovation volume versus pricing and patent expiration pressures. Rod draws a sharp contrast between tech value capture and biopharma value retention to argue why volume growth outpaces pricing erosion. | |
| Evolution to Full Lifecycle Investing and Rocket Pharma | 5 | 3 | 1 | 2 | Ted explores RTW's transition from passive stock picking to active company creation, using Rocket Pharma as a case study. Rod articulates how academic spinouts require full operational incubation rather than standard public market allocation. | |
| Operational Management and Eliminating Fire Drills | 5 | 3 | 1 | 2 | Ted compares hedge fund ego dynamics to academic lab cultures. Rod agrees enthusiastically, describing the two-year operational overhaul needed to eliminate recurring fire drills and blame-shifting. | |
| Management Frameworks: Short Decks and Gantt Charts | 4 | 3 | 1 | 2 | Ted asks about specific management tools that solved organizational bottlenecks. Rod details moving from 300-slide offsite decks to tight four-slide decks and transparent Gantt charts. | |
| Multi-Faceted Deal Sourcing and Research Funnels | 5 | 3 | 1 | 2 | Ted asks about sourcing funnels in an expanding universe of approved drugs. Rod breaks down analyst coverage universes, international outposts, and royalty transaction pipelines. | |
| Analyzing Historical Winners and Multi-Stage Compounding | 6 | 5 | 2 | 3 | Ted inquires about historical winner and loser dynamics. Rod provides a candid case study of shorting Map Pharma, where correct scientific analysis was overturned when Allergan acquired the failing asset. | |
| Probabilistic Frameworks and Management Evaluation | 6 | 4 | 2 | 3 | Ted asks how fundamental science, commercial market size, and management quality interact in valuation. Rod categorizes management teams into three discrete buckets, noting how rare exceptional execution truly is. | |
| Dynamic Probability Assessment and Re-Underwriting | 7 | 5 | 2 | 6 | Ted pushes back with an informed synthesis, stating that he 'scratches his head' reconciling high conviction concentration with dynamic probability adjustments and extreme stock-level volatility. Rod breaks down net/gross positioning and strict 5% stop-loss frameworks. | |
| Private Investing Strategy: Building a Farm Team for Public Markets | 6 | 4 | 2 | 5 | Ted questions why RTW maintains a concentrated book rather than diversifying when achieving an impressive 60-70% hit rate. Rod explains that high-asymmetry, mispriced binary opportunities are too scarce to support broad diversification. | |
| Generating Analytical Edge: Clinical Statistics and Market Sizing | 5 | 6 | 2 | 2 | Ted asks how RTW establishes differential analytical conviction. Rod walks through a detailed masterclass on identifying behavioral placebo biases in Phase 3 constipation trials and epidemiological patient sizing in rare diseases. | |
| Strategic Biopharma Landscape: Blockbusters vs. Mid-Cap Launch Challenges | 5 | 4 | 2 | 2 | Ted asks about structural advantages across the biopharma lifecycle. Rod contrasts blockbuster assets needed for pharma patent cliffs with the funding crisis confronting sub-billion dollar mid-cap launches. | |
| Structural Dynamics of RTW's Listed Investment Vehicle | 5 | 4 | 1 | 2 | Ted inquires into the mechanics of managing a UK-listed investment trust vehicle. Rod explains market illiquidity and the friction of daily mark-to-market pricing for institutional allocators. | |
| Why Biotech Investment Firms Fail | 5 | 5 | 2 | 2 | Ted asks why so many peers in life sciences asset management fail. Rod cites scaling past $1B without institutional process and the fatal tendency of scientifically passionate managers to neglect risk management. | |
| Industry Headwinds: Drug Pricing Pressures and Regulatory Turnover | 5 | 4 | 2 | 2 | Ted asks about macro industry risks. Rod highlights payer pricing resistance and post-COVID FDA staff burnout leading to rigid, bureaucratic regulatory delays. | |
| Closing Questions: Personal Hobbies, Lock-and-Key Bets, and Pet Peeves | 4 | 3 | 1 | 1 | Ted transitions to closing questions on hobbies and investment archetypes. Rod talks about playing guitar and his bias toward 'lock-and-key' genetic replacement bets. | |
| Navigating Crisis: The 2011 AUM Contraction and Resilience | 4 | 2 | 1 | 1 | Ted asks about career crises. Rod recounts the existential 2011 drawdown where AUM plummeted by two-thirds, forcing staff reductions and subleasing office space to survive. | |
| Parental Influences: Independence and Questioning Authority | 4 | 2 | 1 | 1 | Ted closes with questions on parental teachings and life lessons. Rod discusses his father's habit of questioning authority and the humility required to transition from a lone wolf to an organizational leader. |
Statements from this episode (35)
Wong: Long-term biotech investing struggles within non-specialized firms
“I mean, honestly, I think biotech, especially the way we, that I've always done it, which is longer term oriented, is difficult to fit in any larger firm that's not focused only on healthcare.”
Wong: Biotech is in its second-deepest and second-longest bear market ever
“So we are 18 months into a biotech bear market that's the second worst
Correction in the history of the industry, right?
The first being the obvious one, the genomics bubble bursting in 2000 to 2003.
It's second longest, second deepest.”
Wong: Biotech has more than tripled its mature drug production modalities
“We've more than tripled the number of technologies
That you can produce drugs from, and that list I just kind of rattled off, that's not science fiction.
The only things I've named are things that have proven themselves mature enough to actually have drugs com…”
Wong: Biotech innovation boom will drive drug development for decades
“I think it's those two factors that are driving the boom, and I think, you know, it should be a couple decades at least of then improving these modalities, utilizing the information, and just getting a lot more drugs developed.”
Wong: Drug development enjoys relatively strong value capture via pricing
“Drug development is one of the sectors that has relatively good value capture via pricing.”
Wong: Doubling drug approvals to 80 will drive massive biotech value creation
“On average, we've been approving forty-ish drugs a year, and if 40 goes to 80, even if you're losing some on pricing, it should be a tremendous amount of value creation.”
Rod Wong: Healthcare portfolios should be concentrated because mispriced drugs are scarce
“So at the end of the day, the strategy was find those things that offer high probability asymmetric risk reward over a medium to long duration and build a portfolio out of those things, recognizing that great drugs that are underappreciated by the market shoul…”
Wong: Most asset management firms rely on lone wolf culture
“Most asset management firms, even very, very successful people, even big firms are structured as very small teams, sometimes just flat out individuals. There's a lot of lone wolf Culture.”
Wong: Academic lab cultures foster egos that complicate cross-functional management
“They are small teams that are very, very good at what they do. And you develop big personalities, big egos from that. And that's a management challenge when what you're talking about is you want people with different expertise to really come together and work …”
Rod Wong: A great internal presentation deck is probably four slides
“And now, what is a great deck? A great deck is probably four slides.”
Wong: Biotech multi-baggers require multi-stage support over roughly five years
“When you think about what actually drives the business or the returns of the funds, it is finding things early when they're misunderstood or simply no one's paying attention, doing the work, getting convicted, and then supporting it along multiple steps, stage…”
Wong: RTW is wrong on biotech investments 35% to 40% of the time
“We're wrong, you know, high thirties, 40% of the time, 40 some odd percent of the time. But the key is making those losses as small as possible.”
Wong: RTW's second-largest loss was a short position against MAP Pharmaceuticals
“Our second largest loser was actually a short position against a company called Map Pharma. They're developing a single use inhaler for migraine. And the very short version of the story is our research said that That they can't manufacture this stuff.”
Wong: RTW slashed its maximum short position sizing rules
“One adjustment that we made as a result was on our shorts. We slashed the max position size.”
Wong: RTW applies value investing frameworks to binary biotech development
“We're fundamentally value oriented and we are looking for asymmetric risk reward. The trick is that you have to overlay that we live in a probabilistic business or one that's binary.”
Wong: Extreme outliers in biotech management quality are exceedingly rare
“I put things in three basic buckets. Low percentage of the time management that is so stellar. That you think they can take a very marginal product, right? They can sell ice to an Eskimo, and there's drugs like that. And they can find a way to get it across th…”
Wong: Position sizing requires continual re-underwriting of catalyst probabilities
“We just consider each point in time, almost kind of like you're re-underwriting the investment, right? So No matter where an investment is trading or where it's been marked last, you're thinking about then what is the next step in terms of key event, probabili…”
Wong: In Q2 2022 biotech stocks sold off even on positive news
“You know, as an example kind of the worst part of the bear market sell-off, this cycle, Q-two of last year, you could have been right on everything, right? Call the event right, Day the news comes out, the stock trades down because it's a source of liquidity l…”
Wong: RTW limits worst-case position loss to 5% of fund capital
“Our best ideas, this conviction piece, our very best ideas. And sometimes we don't even have one that reaches this level in a given year, but we are willing to take up to a five percent loss if we're flat out wrong.”
Wong: Biotech positions above 5% require commercial revenue support
“So we'll have larger positions that are five to 10% plus of the portfolio. That must mean that those larger positions have some kind of base business value support. They sell a drug on the market, and we're playing for the second drug. And then you have a numb…”
Wong: Strong Phase 2 p-values in constipation drugs repeatedly failed Phase 3
“We studied all these historical constipation trials, going back into the literature, and we found that phase twos, a lot of them work, and phase threes, they all fail, every single one. So empirically, we said, actually, the statistician is wrong. Doesn't matt…”
Wong: Sizing rare disease markets via center counts and genetics provides RTW edge
“And we've got very good at doing exercises by, for example, counting patients at certain centers, by knowing how to use insurance data, more recently knowing how to use genetic data from public databases, and using that to conclude what The outcome was likely …”
Wong: Pharma faces major patent cliff and M&A pressure in late 2020s
“And now, in the back half of this decade again, you're going to have these big patent expirations, and it's on higher revenue basis. So there is tremendous pressure in the industry for those companies to try to mitigate Those patent expiries and do deals.”
Wong: Strategic blockbuster biotechs command strong valuations despite market downturns
“So I would say those biotech companies, so the, of the targets the ones that are, that have the best seat in the house are the ones that are developing drugs that have the potential to move the needle for a pharma. So it has to be a blockbuster drug and is in …”
Wong: Biotechs launching sub-billion-dollar drugs face severe commercial funding challenges
“One particular example that we find kind of interesting is that companies that actually have succeeded all the way, you know, through development, and they're getting ready to launch a product, but that product is a sub one billion dollar peak sales product. C…”
Wong: UK listed funds suffer from illiquidity and a shallow investor base
“I think the challenge is that UK in general, and then specifically for listed funds, there's not a deep audience and there's not a lot of liquidity for that.”
Wong: Around a dozen dedicated healthcare firms manage over $1B
“I don't know the exact number, but healthcare dedicated firms that are managing meaningful amounts of capital, like north of a billion dollars is probably, you know, a dozen plus or minus something like that.”
Wong: Healthcare investment culture defaults to collaboration over competition
“The culture that developed in our ecosystem was one that we worked together to get things. So most of us are friends with some portion of the rest of us. And the culture is to default to not be competitive, but try to be collaborative. And that spirit, I think…”
Wong: Lone-wolf leadership and lack of structure cause scaling biotech firms to fail
“It's very hard, especially when the wiring of your leadership, everything that's gotten them to that point are the same things that will cause their business to fail. Being a lone wolf, not embracing teamwork, not embracing structure. I think that's one key th…”
Wong: Biotech investors fail when passion for science overrides risk management
“I think another key thing is falling in love with science and not doing the risk management part of the job properly.”
Wong: Biotech needs optimization of existing modalities, not new ones
“And I actually think that we don't need to increase the number of modalities at all. If we just focused on improving what we have, this new updated list, I think that would last the industry 10 to 20 years.”
Rod Wong: Payer pushback on drug pricing is biotech's top long-term risk
“You know, I think one of the things I'm most concerned about is payers and the pressure that we're seeing on paying for innovation in drug development. That's probably my number one long-term concern.”
Rod Wong: FDA staff turnover is driving more conservative regulatory decisions
“COVID actually had a major impact on how the FDA functions. They moved heaven and earth to get those vaccines and the first handful of drugs approved. It burned a lot of people out. And so you had tremendous turnover at FDA and there's a whole training process…”
Wong: Equity offerings are typically capped at 10% to 20% of market cap
“You know, the rough rule of thumb is you can do an equity offering for like, 10 to 20% of a company's market cap at any given time. But some companies need three, four X that amount of capital.”
Wong: 'Lock-and-key' biotech bets have high clinical odds and strong returns
“If you know that a tumor is caused by this mutation, or if you know that this rare disease, they are missing this gene, and if you can express the protein that's missing or replace it, that's probably going to work. And as simple as it sounds, we continue to m…”